WO2005034909A3 - Complexes proteine-proteophore - Google Patents

Complexes proteine-proteophore Download PDF

Info

Publication number
WO2005034909A3
WO2005034909A3 PCT/EP2004/010973 EP2004010973W WO2005034909A3 WO 2005034909 A3 WO2005034909 A3 WO 2005034909A3 EP 2004010973 W EP2004010973 W EP 2004010973W WO 2005034909 A3 WO2005034909 A3 WO 2005034909A3
Authority
WO
WIPO (PCT)
Prior art keywords
cleavable linker
hyperbranched polymer
via non
polymer conjugates
conjugates via
Prior art date
Application number
PCT/EP2004/010973
Other languages
English (en)
Other versions
WO2005034909A2 (fr
Inventor
Dirk Vetter
Ulrich Hersel
Harald Rau
Robert Schnepf
Thomas Wegge
Original Assignee
Complex Biosystems Gmbh
Dirk Vetter
Ulrich Hersel
Harald Rau
Robert Schnepf
Thomas Wegge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Complex Biosystems Gmbh, Dirk Vetter, Ulrich Hersel, Harald Rau, Robert Schnepf, Thomas Wegge filed Critical Complex Biosystems Gmbh
Priority to EP04765740.8A priority Critical patent/EP1682186B1/fr
Priority to ES04765740.8T priority patent/ES2451622T3/es
Priority to EP16160207.3A priority patent/EP3085388B1/fr
Priority to US10/574,213 priority patent/US7879588B2/en
Priority to DK04765740.8T priority patent/DK1682186T3/en
Publication of WO2005034909A2 publication Critical patent/WO2005034909A2/fr
Publication of WO2005034909A3 publication Critical patent/WO2005034909A3/fr
Priority to US12/967,285 priority patent/US8450097B2/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/701—Integrated with dissimilar structures on a common substrate
    • Y10S977/702—Integrated with dissimilar structures on a common substrate having biological material component
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/701—Integrated with dissimilar structures on a common substrate
    • Y10S977/702—Integrated with dissimilar structures on a common substrate having biological material component
    • Y10S977/705—Protein or peptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/754—Dendrimer, i.e. serially branching or "tree-like" structure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Polyethers (AREA)

Abstract

L'invention concerne une composition comprenant un polymère hyperramifié fixé à un noyau et une fraction biologiquement active. La fraction biologiquement active est fixée au noyau au moyen d'un lieur L sensiblement non clivable enzymatiquement. Cette composition peut être utilisée pour administrer la fraction biologiquement active dans sa cible.
PCT/EP2004/010973 2003-10-02 2004-10-01 Complexes proteine-proteophore WO2005034909A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP04765740.8A EP1682186B1 (fr) 2003-10-02 2004-10-01 Conjugués de polymères hyperramifiés via des liaisons clivables par moyens non-enzymatiques
ES04765740.8T ES2451622T3 (es) 2003-10-02 2004-10-01 Conjugados de polímeros hiperramificados a través de enlazante escindible no enzimático
EP16160207.3A EP3085388B1 (fr) 2003-10-02 2004-10-01 Conjugués de polymères hyperramifiés par liaisons non-enzymatiquement clivables
US10/574,213 US7879588B2 (en) 2003-10-02 2004-10-01 Protein-proteophore complexes
DK04765740.8T DK1682186T3 (en) 2003-10-02 2004-10-01 HYPERFORCHED POLYMER CONJUGATES THROUGH NON-ENZYMATIC SPLIT LINKERS
US12/967,285 US8450097B2 (en) 2003-10-02 2010-12-14 Protein-proteophore complexes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03022097.4 2003-10-02
EP03022097A EP1525890A1 (fr) 2003-10-02 2003-10-02 Complexes protéine-protéophore

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10574213 A-371-Of-International 2004-10-01
US12/967,285 Continuation US8450097B2 (en) 2003-10-02 2010-12-14 Protein-proteophore complexes

Publications (2)

Publication Number Publication Date
WO2005034909A2 WO2005034909A2 (fr) 2005-04-21
WO2005034909A3 true WO2005034909A3 (fr) 2005-12-08

Family

ID=34384573

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/010973 WO2005034909A2 (fr) 2003-10-02 2004-10-01 Complexes proteine-proteophore

Country Status (10)

Country Link
US (2) US7879588B2 (fr)
EP (4) EP1525890A1 (fr)
CY (2) CY1114972T1 (fr)
DK (2) DK1682186T3 (fr)
ES (2) ES2600729T3 (fr)
HU (1) HUE030243T2 (fr)
PL (1) PL2090323T3 (fr)
PT (1) PT2090323T (fr)
SI (1) SI2090323T1 (fr)
WO (1) WO2005034909A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12016903B2 (en) 2014-11-21 2024-06-25 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone treatment

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0988112B1 (fr) * 1997-06-20 2010-04-14 New York University Electrovaporisation de solutions de substances pour la fabrication en masse de biopuces et de bibliotheques de biopuces
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
ATE533513T1 (de) 2002-09-06 2011-12-15 Cerulean Pharma Inc Polymere auf basis von cyclodextrin zur verabreichung von an diese kovalent gebundene arzneimittel
BR122019000248B8 (pt) 2004-03-23 2021-07-27 Complex Biosystems Gmbh reagente de ligador de pró-fármaco de cascata polimérico
EP2594291A1 (fr) * 2004-07-05 2013-05-22 Ascendis Pharma GmbH Hydrogel
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
EP1625856A1 (fr) * 2004-08-13 2006-02-15 Complex Biosystems GmbH Hydrogel conjugé polymèrique d'une prodrogue
WO2006108052A2 (fr) 2005-04-06 2006-10-12 Genzyme Corporation Ciblage de glycoproteines therapeutiques
PL1940905T3 (pl) * 2005-10-25 2011-02-28 Evonik Degussa Gmbh Preparaty zawierające hiperrozgałęzione polimery
JP5401095B2 (ja) 2005-11-17 2014-01-29 ゾゲニクス インコーポレーティッド 無針注射による粘性製剤の送達方法
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
TW201509433A (zh) * 2006-12-13 2015-03-16 Cerulean Pharma Inc 用於醫物傳遞之以環糊精為基之聚合物
PL2121713T3 (pl) 2007-01-18 2013-11-29 Genzyme Corp Oligosacharydy zawierające grupę aminooksylową oraz ich koniugaty
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
EP1982698A1 (fr) * 2007-04-18 2008-10-22 Evonik Degussa GmbH Préparation destinée à la libération commandée de matériaux naturels bioactifs
AU2008258548B2 (en) 2007-06-08 2014-07-10 Sanofi-Aventis Deutschland Gmbh Long-acting transient polymer conjugates of exendin
US10463609B2 (en) 2007-10-05 2019-11-05 Wayne State University Dendrimers for sustained release of compounds
EP2756756B1 (fr) 2008-04-28 2016-01-06 Zogenix, Inc. Compositions inédites destinées au traitement de la migraine
ES2875426T3 (es) 2008-04-29 2021-11-10 Ascendis Pharma Endocrinology Div A/S Compuestos de hormona de crecimiento humana recombinante pegilada
EP2113256A1 (fr) 2008-04-29 2009-11-04 Ascendis Pharma AS Dérivés pégylés du rhGH
DE102008042923A1 (de) 2008-10-17 2010-04-22 Evonik Goldschmidt Gmbh Präparate zur gesteuerten Freisetzung von Wirkstoffen
EP3608330B1 (fr) 2008-12-16 2022-11-09 Genzyme Corporation Intermédiaires synthétiques utiles dans la préparation des conjugués oliogosaccharide-protéine
AU2010220324A1 (en) 2009-03-05 2011-09-01 Ascendis Pharma As Interferon alpha carrier prodrugs
PL2432489T3 (pl) 2009-05-20 2017-05-31 Biomarin Pharmaceutical Inc. Warianty peptydu natriuretycznego typu C
SG178193A1 (en) 2009-07-31 2012-03-29 Sanofi Aventis Deutschland Prodrugs comprising an insulin linker conjugate
AU2010277560B2 (en) 2009-07-31 2014-12-11 Sanofi-Aventis Deutschland Gmbh Long acting insulin composition
EP2470287A4 (fr) 2009-08-28 2015-01-21 Univ Columbia Systèmes, procédés, et dispositifs de production de microbulles remplies de gaz
EP2485712A1 (fr) 2009-10-06 2012-08-15 Ascendis Pharma A/S Composition sous-cutanée de palipéridone
KR101756493B1 (ko) 2009-10-29 2017-07-10 아센디스 파마 에이에스 생분해성 하이드로겔의 살균
RU2012129674A (ru) 2009-12-15 2014-01-27 Аспендис Фарма Ас Композиция гормона роста
FR2955111B1 (fr) 2010-01-12 2013-05-31 Biomerieux Sa Procede de preparation de composes polybiotinyles
WO2011089215A1 (fr) 2010-01-22 2011-07-28 Ascendis Pharma As Lieurs de promédicaments à base de dipeptides pour des médicaments à teneur en amine aromatique
DK2525830T3 (en) 2010-01-22 2016-08-15 Ascendis Pharma As DIPEPTID-BASED PRODRUG LINKERS TO ALIFATIC AMINE-CONTAINING MEDICINES
WO2011089214A1 (fr) 2010-01-22 2011-07-28 Ascendis Pharma As Lieurs de précurseurs à base de carbamates liés à des supports
WO2012030675A1 (fr) * 2010-08-28 2012-03-08 The Trustees Of Columbia University In The City Of New York Systèmes, procédés, et dispositifs de transfection plasmidique de gènes à l'aide de microbulles modifiées par un polymère
EP2438930A1 (fr) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Promédicaments comprenant un conjugué de liaison d'exendine
EP2592103A1 (fr) 2011-11-08 2013-05-15 Adriacell S.p.A. Dérivés d'aldéhyde de polymère
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
JP2017518431A (ja) * 2014-05-23 2017-07-06 スリーエム イノベイティブ プロパティズ カンパニー 不連続シリコーン接着剤物品
US20200188524A1 (en) * 2016-09-22 2020-06-18 University Of Washington Molecular logic gates for controlled material degradation
EP3960203A1 (fr) 2020-08-25 2022-03-02 Université de Liège Complexes pour l'administration d'agents protéiques
CA3190861A1 (fr) 2020-08-28 2022-03-03 Amr Abdelmonem Procede et systeme d'attenuation d'interference en champ proche
US11502404B1 (en) 2022-03-31 2022-11-15 Isco International, Llc Method and system for detecting interference and controlling polarization shifting to mitigate the interference
US11476585B1 (en) 2022-03-31 2022-10-18 Isco International, Llc Polarization shifting devices and systems for interference mitigation
US11476574B1 (en) 2022-03-31 2022-10-18 Isco International, Llc Method and system for driving polarization shifting to mitigate interference
US11509072B1 (en) 2022-05-26 2022-11-22 Isco International, Llc Radio frequency (RF) polarization rotation devices and systems for interference mitigation
US11515652B1 (en) 2022-05-26 2022-11-29 Isco International, Llc Dual shifter devices and systems for polarization rotation to mitigate interference
US11509071B1 (en) 2022-05-26 2022-11-22 Isco International, Llc Multi-band polarization rotation for interference mitigation
US11985692B2 (en) 2022-10-17 2024-05-14 Isco International, Llc Method and system for antenna integrated radio (AIR) downlink and uplink beam polarization adaptation
US11956058B1 (en) 2022-10-17 2024-04-09 Isco International, Llc Method and system for mobile device signal to interference plus noise ratio (SINR) improvement via polarization adjusting/optimization
US11949489B1 (en) 2022-10-17 2024-04-02 Isco International, Llc Method and system for improving multiple-input-multiple-output (MIMO) beam isolation via alternating polarization
US11990976B2 (en) 2022-10-17 2024-05-21 Isco International, Llc Method and system for polarization adaptation to reduce propagation loss for a multiple-input-multiple-output (MIMO) antenna
CN117959250A (zh) * 2024-03-27 2024-05-03 长春生物制品研究所有限责任公司 一种重组人白细胞介素-1受体拮抗剂注射液

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031231A1 (fr) * 1995-04-04 1996-10-10 Elan Corporation, Plc Nanoparticules biodegradables a liberation lente renfermant de l'insuline
WO2001007469A2 (fr) * 1999-07-23 2001-02-01 Les Laboratoires Servier Dendrimeres polypeptidiques en tant que porteurs unimoleculaires d'agents de contraste d'imagerie diagnostique, de substances bioactives et de medicaments
US20020054863A1 (en) * 1997-07-07 2002-05-09 Navid Malik Method of treating cancerous tumors with a dendritic-platinate drug delivery system and a process for preparing that system
US6410680B1 (en) * 2000-06-21 2002-06-25 Dendrimolecular, Inc. Dendrimer constructs and metal complexes thereof having superoxide dismutase activity
WO2003000777A2 (fr) * 2001-01-19 2003-01-03 Shearwater Corporation Copolymeres sequences a bras multiples utilises comme vehicules pour l'administration de medicaments
WO2003057716A2 (fr) * 2002-01-08 2003-07-17 New River Pharmaceuticals, Inc. Encapsulation dendritique d'agents actifs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507466A (en) 1983-01-07 1985-03-26 The Dow Chemical Corporation Dense star polymers having core, core branches, terminal groups
US5714166A (en) * 1986-08-18 1998-02-03 The Dow Chemical Company Bioactive and/or targeted dendrimer conjugates
ES2054678T5 (es) 1986-08-18 1997-09-16 Dow Chemical Co Conjugados estrella.
DE4310141A1 (de) 1993-03-29 1994-10-06 Boehringer Mannheim Gmbh Homobidentale trifunktionelle Linker
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
JP4465109B2 (ja) 1997-12-17 2010-05-19 エンゾン ファーマシューティカルズ，インコーポレーテッド アミノ及びヒドロキシル含有生物活性剤のポリマープロドラッグ
JP2000306221A (ja) * 1999-04-22 2000-11-02 Nec Corp 磁気抵抗効果ヘッドおよびその製造方法
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6323311B1 (en) 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
WO2002068454A2 (fr) * 2001-02-21 2002-09-06 Batelle Memorial Institute Proteines dans un support poreux
US20030068361A1 (en) 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
EP1581583B1 (fr) * 2002-12-30 2010-03-24 Nektar Therapeutics Copolymeres sequences polypeptide-poly(ethylene glycol) ayant plusieurs bras en tant qu'excipients d'apport de medicaments

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031231A1 (fr) * 1995-04-04 1996-10-10 Elan Corporation, Plc Nanoparticules biodegradables a liberation lente renfermant de l'insuline
US20020054863A1 (en) * 1997-07-07 2002-05-09 Navid Malik Method of treating cancerous tumors with a dendritic-platinate drug delivery system and a process for preparing that system
WO2001007469A2 (fr) * 1999-07-23 2001-02-01 Les Laboratoires Servier Dendrimeres polypeptidiques en tant que porteurs unimoleculaires d'agents de contraste d'imagerie diagnostique, de substances bioactives et de medicaments
US6410680B1 (en) * 2000-06-21 2002-06-25 Dendrimolecular, Inc. Dendrimer constructs and metal complexes thereof having superoxide dismutase activity
WO2003000777A2 (fr) * 2001-01-19 2003-01-03 Shearwater Corporation Copolymeres sequences a bras multiples utilises comme vehicules pour l'administration de medicaments
WO2003057716A2 (fr) * 2002-01-08 2003-07-17 New River Pharmaceuticals, Inc. Encapsulation dendritique d'agents actifs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JANSEN J F G A ET AL: "ENCAPSULATION OF GUEST MOLECULES INTO A DENDRITIC BOX", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 266, no. 5188, 18 November 1994 (1994-11-18), pages 1226 - 1229, XP000500113, ISSN: 0036-8075 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12016903B2 (en) 2014-11-21 2024-06-25 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone treatment

Also Published As

Publication number Publication date
EP2090323A1 (fr) 2009-08-19
US7879588B2 (en) 2011-02-01
US20070020224A1 (en) 2007-01-25
PL2090323T3 (pl) 2017-01-31
ES2600729T3 (es) 2017-02-10
DK1682186T3 (en) 2014-03-03
WO2005034909A2 (fr) 2005-04-21
SI2090323T1 (sl) 2016-11-30
EP1525890A1 (fr) 2005-04-27
EP1682186B1 (fr) 2013-12-11
EP3085388A1 (fr) 2016-10-26
US20110172390A1 (en) 2011-07-14
EP3085388B1 (fr) 2021-04-07
CY1114972T1 (el) 2016-12-14
CY1119457T1 (el) 2018-04-04
US8450097B2 (en) 2013-05-28
PT2090323T (pt) 2016-11-02
ES2451622T3 (es) 2014-03-28
EP1682186A2 (fr) 2006-07-26
DK2090323T3 (en) 2016-11-07
HUE030243T2 (en) 2017-04-28
EP2090323B1 (fr) 2016-07-27

Similar Documents

Publication Publication Date Title
WO2005034909A3 (fr) Complexes proteine-proteophore
AU2001257577A1 (en) Water-soluble polymer conjugates of artelinic acid
RS52891B (en) GASTRORE-RESISTANT PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMINE
WO2007144709A3 (fr) DÉRIVÉS de LEPTOMYCINE
WO2007098128A3 (fr) Formules liquides de phényléphrine
IL169045A (en) Immunoconjugates
AU2001269936A1 (en) Transgenic algae for delivering antigens to an animal
CR8093A (es) Composicion de farmaco conjugado
WO2006138463A3 (fr) Compositions polymeres et conjugues de medicaments anti-inflammatoires non steroides
AU2001259846A1 (en) Methods and compositions for enhancing the delivery of a nucleic acid to a cell
WO2004060405A8 (fr) Composes et compositions reagissant avec des tissus et utilisations associees
WO2009100194A3 (fr) Conjugués à fraction de liaison à la camptothécine
WO2004091517A3 (fr) Conjugues comprenant l'interleukine 18 humaine il 18 et mutants de ces conjugues par substitution
AU2001280767A1 (en) Peptide-mediated delivery of molecules into cells
AU2003215245A1 (en) Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
EP1649864A4 (fr) Composition therapeutique et/ou preventive pour parodontopathies
AU2003301410A1 (en) Polymeric materials for site specific delivery to the body
AU2001279664A1 (en) Endoparasiticidal agents for voluntary oral ingestion by animals
AU2003225432A1 (en) Delivery of a substance to a pre-determined site
WO2004108747A3 (fr) Conjugues de lectine
AU2002245031A1 (en) Compositions and methods relating to prostate specific genes and proteins
WO2004112717A3 (fr) Conjugue destine au ciblage specifique d'agents anticancereux sur des cellules cancereuses, et production du conjugue
WO2004045491A3 (fr) Elimination de cellule ciblee par l'intermediaire d'un arn double brin
AU2003265960A1 (en) Method of preparing amino acid taxane derivatives and polymer conjugates containing the same
AU2003267602A1 (en) Polymer compositions for administration to animals

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004765740

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004765740

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007020224

Country of ref document: US

Ref document number: 10574213

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10574213

Country of ref document: US